Christophe Weber (Miho Takahashi/The Yomiuri Shimbun via AP Images)
December 22, 2021 10:19 AM EST
FDA+

Months af­ter miss­ing its PDU­FA date, FDA slaps down Takeda's old Shire drug for eosinophilic esophagi­tis

Nicole DeFeudis

Editor

Take­da CEO Christophe We­ber thought he had a win in the bag for TAK-721 — one of the ex­per­i­men­tal drugs spot­light­ed in the com­pa­ny’s

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J takes 340B fight with fed­er­al gov­ern­ment to court

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

Ex­clu­sive: Flag­ship names two CEO-part­ners to lead Va­lo Health, Apri­ori Bio

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times